Why therapeutic drug monitoring is needed for monoclonal antibodies and how do we implement this?

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 4, 2016, Pages 351-354

  Mould, D R ^a  

^a Projections Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DACLIZUMAB; DRUG ANTIBODY; GOLIMUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT;

CANCER THERAPY; DECISION SUPPORT SYSTEM; DRUG CLEARANCE; DRUG EXPOSURE; DRUG INDUSTRY; DRUG MONITORING; DRUG TREATMENT FAILURE; HUMAN; INFLAMMATORY DISEASE; PRIORITY JOURNAL; REVIEW; DOSE CALCULATION; DOSE RESPONSE; PREDICTIVE VALUE; PROCEDURES; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DECISION SUPPORT TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; HUMANS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84960448691     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.278     Document Type: Review

References (10)

1. Ordás, I., Mould, D.R., Feagan, B.G., &, Sandborn, W.J., Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin. Pharmacol. Ther. 91, 635-646 (2012).
2. St Clair, E.W., et al,. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 1451-1459 (2002).
3. Menting, S.P., et al,. Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: A step toward personalized treatment. JAMA Dermatol. 151, 616-622 (2015).
4. Oude Munnink, T.H., Henstra, M.J., Segerink, L.I., Movig, K.L., &, Brummelhuis-Visser, P., Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease-Translating TNF-α experience to oncology. Clin. Pharmacol. Ther. (2015); e-pub ahead of print.
5. Seow, C.H., Newman, A., Irwin, S.P., Steinhart, A.H., Silverberg, M.S., &, Greenberg, G.R., Trough serum infliximab: A predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 59, 49-54 (2010).
6. Steenholdt, C., et al,. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: A randomised, controlled trial. Gut 63, 919-927 (2014).
7. Jani, M., et al,. Clinical utility of random anti-Tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-Term treatment response in rheumatoid arthritis. Arthritis Rheumatol. 67, 2011-2019 (2015).
8. Mould, D.R., et al,. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br. J. Clin. Pharmacol. 64, 278-291 (2007).
9. Han, K., Jin, J., Maia, M., Lowe, J., Sersch, M.A., &, Allison, D.E., Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: Analysis of individual data from AVAGAST phase III trial. AAPS J. 16, 1056-1063 (2014).
10. Iannone, F., Fanizzi, R., Notarnicola, A., Scioscia, C., Anelli, M.G., &, Lapadula, G., Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients. Joint Bone Spine 82, 187-191 (2015).